These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31868826)

  • 1. Role of NFATc1 in the Bone-Vascular Axis Calcification Paradox.
    Gu W; Wang Z; Sun Z; Bao Z; Zhang L; Geng Y; Jing L; Mao X; Li L
    J Cardiovasc Pharmacol; 2020 Mar; 75(3):200-207. PubMed ID: 31868826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.
    Harper E; Forde H; Davenport C; Rochfort KD; Smith D; Cummins PM
    Vascul Pharmacol; 2016 Jul; 82():30-40. PubMed ID: 26924459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
    Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
    Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Action of RANKL and OPG for osteoclastogenesis.
    Kobayashi Y; Udagawa N; Takahashi N
    Crit Rev Eukaryot Gene Expr; 2009; 19(1):61-72. PubMed ID: 19191757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into osteoclastogenic signaling mechanisms.
    Nakashima T; Hayashi M; Takayanagi H
    Trends Endocrinol Metab; 2012 Nov; 23(11):582-90. PubMed ID: 22705116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The function and meaning of receptor activator of NF-κB ligand in arterial calcification.
    Nie B; Zhou SQ; Fang X; Zhang SY; Guan SM
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):666-671. PubMed ID: 26489619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling.
    Kim JY; Kim JY; Kim JJ; Oh J; Kim YC; Lee MS
    Biol Pharm Bull; 2014; 37(2):255-61. PubMed ID: 24492722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification.
    Osako MK; Nakagami H; Shimamura M; Koriyama H; Nakagami F; Shimizu H; Miyake T; Yoshizumi M; Rakugi H; Morishita R
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1287-96. PubMed ID: 23580147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidized low density lipoprotein enhanced RANKL expression in human osteoblast-like cells. Involvement of ERK, NFkappaB and NFAT.
    Mazière C; Salle V; Gomila C; Mazière JC
    Biochim Biophys Acta; 2013 Oct; 1832(10):1756-64. PubMed ID: 23756197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
    Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
    Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation.
    Fuji H; Ohmae S; Noma N; Takeiri M; Yasutomi H; Izumi K; Ito M; Toyomoto M; Iwaki S; Takemoto K; Seo S; Taura K; Hida S; Aoyama M; Ishihama Y; Hagiwara M; Takeda N; Hatano E; Iwaisako K; Uemoto S; Asagiri M
    Biochem Biophys Res Commun; 2018 Sep; 503(2):544-549. PubMed ID: 29800570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the osteoclastogenic RANKL-RANK axis prevents osteoporotic bone loss and soft tissue calcification in coxsackievirus B3-infected mice.
    Lee K; Kim H; Park HS; Kim KJ; Song H; Shin HI; Kim HS; Seo D; Kook H; Ko JH; Jeong D
    J Immunol; 2013 Feb; 190(4):1623-30. PubMed ID: 23303667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular calcification: an update on mechanisms and challenges in treatment.
    Wu M; Rementer C; Giachelli CM
    Calcif Tissue Int; 2013 Oct; 93(4):365-73. PubMed ID: 23456027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    D'Amelio P; Isaia G; Isaia GC
    J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethyl Acetate Fraction of Aqueous Extract of Lentinula edodes Inhibits Osteoclastogenesis by Suppressing NFATc1 Expression.
    Lee H; Lee K; Lee S; Lee J; Jeong WT; Lim HB; Hyun TK; Yi SJ; Kim K
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.